Edgewise Therapeutics, Inc. EWTX Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Edgewise Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: Edgewise Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Edgewise Therapeutics, Inc.'s retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Edgewise Therapeutics, Inc.'s retained earnings?
- Edgewise Therapeutics, Inc. (EWTX) reported retained earnings of -$595.38M in Q1 2026.
- How has Edgewise Therapeutics, Inc.'s retained earnings changed year-over-year?
- Edgewise Therapeutics, Inc.'s retained earnings decreased by 42.0% year-over-year, from -$419.37M to -$595.38M.
- What is the long-term trend for Edgewise Therapeutics, Inc.'s retained earnings?
- Over 5 years (2020 to 2025), Edgewise Therapeutics, Inc.'s retained earnings has grown at a 74.1% compound annual growth rate (CAGR), from -$34.15M to -$546.37M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.